Compare ROC & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROC | INO |
|---|---|---|
| Founded | 2015 | 1979 |
| Country | United States | United States |
| Employees | 82 | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.2M | 90.5M |
| IPO Year | N/A | 1999 |
| Metric | ROC | INO |
|---|---|---|
| Price | $4.67 | $1.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $9.00 | $6.75 |
| AVG Volume (30 Days) | 36.1K | ★ 1.6M |
| Earning Date | 03-31-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | $20,156.19 |
| Revenue Next Year | N/A | $421.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $4.36 | $1.03 |
| 52 Week High | $7.80 | $2.86 |
| Indicator | ROC | INO |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 41.74 |
| Support Level | $4.42 | $1.03 |
| Resistance Level | $5.32 | $1.23 |
| Average True Range (ATR) | 0.39 | 0.06 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 15.96 | 22.92 |
Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.